Matinas biopharma reports successful treatment of patient with limb-threatening mucor infection in its oral mat2203 compassionate/expanded use access program

Bedminster, n.j., june 24, 2024 (globe newswire) -- matinas biopharma holdings, inc. (nyse american: mtnb), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (lnc) platform delivery technology, announces the recent successful treatment of a 22-year-old male with polymicrobial necrotizing fasciitis (flesh-eating disease) that involved drug-resistant lichtheimia, an angio-invasive species of the fungus mucorales. this patient was treated at new york presbyterian/weill cornell medical center and was discharged after just six weeks of treatment with mat2203, matinas' oral formulation of the potent antifungal amphotericin b. the patient was treated under matinas' compassionate/ expanded use access program by sharan yadav, md, infectious disease fellow.
MTNB Ratings Summary
MTNB Quant Ranking